Skip to main content

Advertisement

SpringerLink
Log in

A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Renal cell carcinoma (RCC) is an uncommon malignancy whose incidence has been increasing over the past few decades, posing treatment challenges for elderly or infirm patients who are not surgical candidates. Stereotactic ablative radiotherapy (SABR) has emerged as a promising non-invasive treatment modality for RCC. The high dose-per-fraction used in SABR overcomes some of the mechanisms of radioresistance that has hindered the effective treatment of RCC with conventional radiotherapy. For primary RCC, local control rates for SABR exceed 90%, with typically minimal grade 3 or higher toxicities, offering a viable alternative for inoperable patients and those not eligible for or unable to tolerate radiofrequency or cryotherapy ablation. SABR can also be used in patients with a solitary kidney as a strategy for renal preservation to avoid need for dialysis. Given its excellent local control rates, low toxicity and preservation of renal function, SABR offers an attractive alternative to more invasive modalities for treatment of localized RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V et al (2019) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 30(5):706–720

    Article  CAS  PubMed  Google Scholar 

  2. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335(12):865–875

    Article  CAS  PubMed  Google Scholar 

  3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209–249

    Article  Google Scholar 

  4. Saad AM, Gad MM, Al-Husseini MJ, Ruhban IA, Sonbol MB, Ho TH (2019) Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study. Clin Genitourin Cancer 17(1):46-57.e5

    Article  PubMed  Google Scholar 

  5. Hock LM, Lynch J, Balaji KC (2002) Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 167(1):57–60

    Article  PubMed  Google Scholar 

  6. Campi R, Rebez G, Klatte T, Roussel E, Ouizad I, Ingels A et al (2023) Effect of smoking, hypertension and lifestyle factors on kidney cancer - perspectives for prevention and screening programmes. Nat Rev Urol 20(11):669–681

    Article  PubMed  Google Scholar 

  7. King SC, Pollack LA, Li J, King JB, Master VA (2014) Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010. J Urol 191(6):1665–1670

    Article  PubMed  PubMed Central  Google Scholar 

  8. Deschavanne PJ, Fertil B (1996) A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys 34(1):251–266

    Article  CAS  PubMed  Google Scholar 

  9. Ning S, Trisler K, Wessels BW, Knox SJ (1997) Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in Vitro and in Vivo in human renal cell carcinoma xenografts. Cancer 80(S12):2519–2528

    Article  CAS  PubMed  Google Scholar 

  10. Leksell L (1951) The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 102(4):316–319

    CAS  PubMed  Google Scholar 

  11. Takeuchi H, Yoshida M, Kubota T, Ishii H, Sato K, Handa Y et al (2003) Frameless stereotactic radiosurgery with mobile CT, mask immobilization and micro-multileaf collimators. Minim Invasive Neurosurg 46(2):82–85

    Article  CAS  PubMed  Google Scholar 

  12. Meeks SL, Bova FJ, Wagner TH, Buatti JM, Friedman WA, Foote KD (2000) Image localization for frameless stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 46(5):1291–1299

    Article  CAS  PubMed  Google Scholar 

  13. Kuo JS, Yu C, Petrovich Z, Apuzzo MLJ (2008) The Cyberknife stereotactic radiosurgery system: description, installation, and an initial evaluation of use and functionality. Neurosurgery 62:SHC

    Article  Google Scholar 

  14. Qian G, Lowry J, Silverman P, Grosman I, Makara D, Lederman G (2003) Stereotactic extra-cranial radiosurgery for renal cell carcinoma. Int J Radiat Oncol Biol Phys 57(2):S283

    Article  Google Scholar 

  15. Zoumpourlis P, Genovese G, Tannir NM, Msaouel P (2021) Systemic therapies for the management of non-clear cell renal cell carcinoma: what works, what doesn’t, and what the future holds. Clin Genitourin Cancer 19(2):103–116

    Article  PubMed  Google Scholar 

  16. Siva S, Kothari G, Muacevic A, Louie AV, Slotman BJ, Teh BS et al (2017) Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol 14(9):549–563

    Article  PubMed  Google Scholar 

  17. NCCN (2023) NCCN Guidelines Version 1.2024 Kidney Cancer. Available from: https://www.nccn.org/guidelines/guidelines-detail

  18. Siva S, Ellis RJ, Ponsky L, Teh BS, Mahadevan A, Muacevic A et al (2016) Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol 12(5):637–645

    Article  CAS  PubMed  Google Scholar 

  19. Psutka SP, Heidenreich M, Boorjian SA, Bailey GC, Cheville JC, Stewart-Merrill SB et al (2017) Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes. BJU Int 119(1):116–127

    Article  PubMed  Google Scholar 

  20. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z (1994) Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 12(1):206–212

    Article  CAS  PubMed  Google Scholar 

  21. Ray S, Cheaib JG, Pierorazio PM (2020) Active surveillance for small renal masses. Rev Urol 22(1):9–16

    PubMed  PubMed Central  Google Scholar 

  22. Kunkle DA, Uzzo RG (2008) Cryoablation or radiofrequency ablation of the small renal mass. Cancer 113(10):2671–2680

    Article  PubMed  Google Scholar 

  23. Andrews JR, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A et al (2019) Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 76(2):244–251

    Article  PubMed  Google Scholar 

  24. Svedman C, Sandström P, Pisa P, Blomgren H, Lax I, Kälkner KM et al (2006) A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 45(7):870–875

    Article  PubMed  Google Scholar 

  25. Siva S, Ali M, Correa RJM, Muacevic A, Ponsky L, Ellis RJ et al (2022) 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol 23(12):1508–1516

    Article  CAS  PubMed  Google Scholar 

  26. Correa RJM, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L et al (2019) The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis. Eur Urol Focus 5(6):958–969

    Article  PubMed  Google Scholar 

  27. Grubb WR, Ponsky L, Lo SS, Kharouta M, Traughber B, Sandstrom K et al (2021) Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma. Radiother Oncol 1(155):138–143

    Article  Google Scholar 

  28. Siva S, Pham D, Gill S, Corcoran NM, Foroudi F (2012) A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int 110(11 Pt B):E737–E743

    PubMed  Google Scholar 

  29. Ponsky L, Lo SS, Zhang Y, Schluchter M, Liu Y, Patel R et al (2015) Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma. Radiother Oncol 117(1):183–187

    Article  PubMed  Google Scholar 

  30. Staehler M, Bader M, Schlenker B, Casuscelli J, Karl A, Roosen A et al (2015) Single fraction radiosurgery for the treatment of renal tumors. J Urol 193(3):771–775

    Article  PubMed  Google Scholar 

  31. Teh B, Bloch C, Galli-Guevara M, Doh L, Richardson S, Chiang S et al (2007) The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed Imaging Interv J 3(1):e6

    PubMed  PubMed Central  Google Scholar 

  32. Pham D, Thompson A, Kron T, Foroudi F, Kolsky MS, Devereux T et al (2014) Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity. Int J Radiat Oncol Biol Phys 90(5):1061–1068

    Article  PubMed  Google Scholar 

  33. Siva S, Pham D, Kron T, Bressel M, Lam J, Tan TH et al (2017) Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int 120(5):623–630

    Article  PubMed  Google Scholar 

  34. Ali M, Mooi J, Lawrentschuk N, McKay RR, Hannan R, Lo SS et al (2022) The role of stereotactic ablative body radiotherapy in renal cell carcinoma. Eur Urol 82(6):613–622

    Article  PubMed  Google Scholar 

  35. Siva S, Louie AV, Warner A, Muacevic A, Gandhidasan S, Ponsky L et al (2018) Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer 124(5):934–942

    Article  PubMed  Google Scholar 

  36. Siva S, Correa RJM, Warner A, Staehler M, Ellis RJ, Ponsky L et al (2020) Stereotactic ablative radiotherapy for ≥T1b primary renal cell carcinoma: a report from the international radiosurgery oncology consortium for kidney (IROCK). Int J Radiat Oncol Biol Phys 108(4):941–949

    Article  PubMed  Google Scholar 

  37. Rabbani F, Herr HW, Almahmeed T, Russo P (2002) Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors. J Clin Oncol 20(9):2370–2375

    Article  PubMed  Google Scholar 

  38. Correa RJM, Louie AV, Staehler M, Warner A, Gandhidasan S, Ponsky L et al (2019) Stereotactic radiotherapy as a treatment option for renal tumors in the solitary kidney: a multicenter analysis from the IROCK. J Urol 201(6):1097–1104

    Article  PubMed  Google Scholar 

  39. Paparel P, Bigot P, Matillon X, Bensalah K, Salomon L, Baumert H et al (2014) Local recurrence after radical nephrectomy for kidney cancer: management and prediction of outcomes. A multi-institutional study. J Surg Oncol 109(2):126–131

    Article  PubMed  Google Scholar 

  40. Liu Y, Zhang X, Ma H, Tian L, Mai L, Long W et al (2022) Locoregional recurrence after nephrectomy for localized renal cell carcinoma: Feasibility and outcomes of different treatment modalities. Cancer Med 11(23):4430–4439

    Article  PubMed  PubMed Central  Google Scholar 

  41. Mootha RK, Butler R, Laucirica R, Scardino PT, Lerner SP (1999) Renal cell carcinoma with an infrarenal vena caval tumor thrombus. Urology 54(3):561

    Article  CAS  PubMed  Google Scholar 

  42. Margulis V, Freifeld Y, Pop LM, Manna S, Kapur P, Pedrosa I et al (2021) Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus—safety lead-in results of a Phase 2 trial. Int J Radiat Oncol Biol Phys 110(4):1135–1142

    Article  PubMed  PubMed Central  Google Scholar 

  43. Freifeld Y, Pedrosa I, Mclaughlin M, Correa RM, Louie AV, Maldonado JA et al (2022) Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. Urol Oncol 40(4):166.e9-166.e13

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Oncology, Kingston Health Science Centre, Kingston, Canada

    Osbert Zalay & Ian Pereira

  2. Ottawa Hospital Cancer Centre, Ottawa Hospital Regional Cancer Program, Ottawa, Canada

    Prateek Mehra, Ian Pereira, Julia Malone & Shawn Malone

Authors
  1. Osbert Zalay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prateek Mehra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ian Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Julia Malone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shawn Malone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shawn Malone.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zalay, O., Mehra, P., Pereira, I. et al. A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma. World J Urol 42, 52 (2024). https://doi.org/10.1007/s00345-023-04731-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00345-023-04731-2

Keywords

Search

Navigation